Altamira Therapeutics Receivables

Altamira Therapeutics (CYTO) currently reports a receivables of $350K as of December 2024. That compares with $75K in the prior-year period — up 369.5% year over year. Use the charts on this page to explore Altamira Therapeutics's receivables history and peer comparisons.

Altamira Therapeutics's receivables increased from $75K to $350K — a 369.5% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Altamira Therapeutics reported $350K in receivables as of December 2024. That compares with $75K in the prior-year period — up 369.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $350K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Altamira Therapeutics, and consider following CYTO for alerts when major investors trade the stock.

Altamira Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $350K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTO with unrelated industries.